A novel immunotherapy

TG6050 is based on a patented viral vector, designed to induce a strong immune response against the tumor. The virus has been optimized to selectively multiply in the tumor, where it will induce an immune response and lead to the production of powerful drugs (IL-12 and anti-CTLA4). The objective: to achieve high concentrations of these drugs only in the tumor, for improved efficacy and fewer side effects than those observed with the systemic administration of these drugs. TG6050 will be administered intravenously, an equally innovative mode of administration for an oncolytic virus. This route of administration makes it possible to target patients with disseminated disease with numerous metastases visible and invisible by medical imaging techniques.